AstraZeneca's Imfinzi Shows Survival Benefit in Limited-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) has demonstrated a statistically significant survival benefit for patients with limited-stage small cell lung cancer (LS-SCLC) who have completed standard chemoradiotherapy. The results from the Phase III ADRIATIC trial, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showed a 27% reduction in the risk of death compared to placebo.

The trial found that 57% of patients treated with Imfinzi were alive at three years, versus 48% in the placebo group. Median overall survival was 55.9 months for Imfinzi compared to 33.4 months for placebo. The risk of disease progression or death was also reduced by 24% with Imfinzi.

Small cell lung cancer (SCLC) is an aggressive disease, and LS-SCLC often recurs rapidly despite initial treatment. These findings represent the first time an immunotherapy has shown a survival benefit in this patient population after concurrent chemoradiotherapy.

AstraZeneca stated it will work with regulatory authorities to make Imfinzi available to these patients. The company highlighted that this marks a potential new standard of care for LS-SCLC, a disease with historically poor outcomes.